Guided Therapeutics And FDA Review Team Agree On Path Forward For Luviva® Advanced Cervical Scan PMA Application

General Agreement reached on key objectives and endpoints for collecting additional patient data

NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today it believes it has reached a general agreement with the U.S. Food and Drug Administration (FDA) on a plan for submitting an approvable application for the LuViva^® Advanced Cervical Scan.

“The objectives of the meeting were certainly met and we were pleased that the Division Director and two Deputy Directors participated. We look forward to working with the new lead reviewer and lead OBGYN physician to obtain U.S. approval for LuViva”

The path forward is a result of a meeting between the company, two leading U.S. OBGYNs and the agency’s reviewers, which include a new lead reviewer and new OBGYN physician. Details of the plan to collect additional patient data with the LuViva are to be finalized over the next two to three months.

“The objectives of the meeting were certainly met and we were pleased that the Division Director and two Deputy Directors participated. We look forward to working with the new lead reviewer and lead OBGYN physician to obtain U.S. approval for LuViva,” said Gene Cartwright, CEO of Guided Therapeutics. “We expect to have the details of the plan worked out with the agency over the next two to three months, which will include submitting a clinical protocol for collecting the additional patient data.

“Once the protocol is finalized, we will conduct the study, analyze the data and present the results to the agency for review, a timeline that entails at least a year before possible approval.”

The company was represented at the meeting by Dr. Leo B. Twiggs, professor emeritus at the Miller School of Medicine, University of Miami and Dr. Daron Ferris, professor at the Medical College of Georgia. Both of whom were principal investigators of the LuViva pivotal clinical trial and are past presidents of the American Society of Colposcopy and Cervical Pathology.

The LuViva is designed to detect cervical pre-cancer without taking a tissue sample and providing a result immediately, unlike any other women’s health cancer detection technology on the market. The LuViva is approved in Europe, Canada and Mexico and is currently available to women in 20 countries.

World-wide, the market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020. Worldwide there are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer.

About LuViva^® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva^® Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva^® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and “Early detection, better outcomes” are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in our prior financings and our ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and subsequent filings.